Next Article in Journal
Detection and Molecular Diversity of Spike Gene of Porcine Epidemic Diarrhea Virus in China
Next Article in Special Issue
Newer Gene Editing Technologies toward HIV Gene Therapy
Previous Article in Journal
CD8 and CD4 T Cells in West Nile Virus Immunity and Pathogenesis
Viruses 2013, 5(10), 2585-2600; doi:10.3390/v5102585
Review

Foamy Virus Vectors for HIV Gene Therapy

1
 and 1,2,*
Received: 1 September 2013; in revised form: 10 October 2013 / Accepted: 16 October 2013 / Published: 22 October 2013
(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)
View Full-Text   |   Download PDF [477 KB, uploaded 22 October 2013]   |   Browse Figures
Abstract: Highly active antiretroviral therapy (HAART) has vastly improved outcomes for patients infected with HIV, yet it is a lifelong regimen that is expensive and has significant side effects. Retroviral gene therapy is a promising alternative treatment for HIV/AIDS; however, inefficient gene delivery to hematopoietic stem cells (HSCs) has so far limited the efficacy of this approach. Foamy virus (FV) vectors are derived from non-pathogenic viruses that are not endemic to the human population. FV vectors have been used to deliver HIV-inhibiting transgenes to human HSCs, and they have several advantages relative to other retroviral vectors. These include an attractive safety profile, broad tropism, a large transgene capacity, and the ability to persist in quiescent cells. In addition, the titers of FV vectors are not reduced by anti-HIV transgenes that affect the production of lentivirus (LV) vectors. Thus FV vectors are very promising for anti-HIV gene therapy. This review covers the advantages of FV vectors and describes their preclinical development for anti-HIV gene therapy.
Keywords: foamy virus; lentivirus; retrovirus; vector; gene therapy; HIV foamy virus; lentivirus; retrovirus; vector; gene therapy; HIV
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Olszko, M.E.; Trobridge, G.D. Foamy Virus Vectors for HIV Gene Therapy. Viruses 2013, 5, 2585-2600.

AMA Style

Olszko ME, Trobridge GD. Foamy Virus Vectors for HIV Gene Therapy. Viruses. 2013; 5(10):2585-2600.

Chicago/Turabian Style

Olszko, Miles E.; Trobridge, Grant D. 2013. "Foamy Virus Vectors for HIV Gene Therapy." Viruses 5, no. 10: 2585-2600.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert